European Academy of Dermatology and Venereology (EADV) Congress 2026
Late-Breaking Oral Presentation
- Abstract LB-339: The integrated 31-gene expression profile (i31-SLNB) identifies patients with a low risk of sentinel lymph node positivity and 31-GEP identifies patients with high 5-year recurrence risk: The largest prospective, multicenter study of GEP for cutaneous melanoma
- Session: D2T01.3 - Late Breaking News
- Room: Hall A
- Date and Time: Thursday, Oct. 1; 14:45 - 15:00 CEST
- Key findings: This multi-center, prospective study enrolled 2,799 patients across 29 U.S. centers to evaluate DecisionDx-Melanoma's ability to predict sentinel lymph node (SLN) positivity and stratify recurrence risk.
- Among 676 patients who underwent SLNB and received an i31-SLNB result, those classified as low risk (<5% predicted risk) had an observed SLN positivity of 4.4%, consistent with the test's predicted risk of less than 5%. By comparison, patients classified as high risk (>10% predicted risk) had an observed SLN positivity rate of 22.8%.
- Among 565 SLNB-eligible patients with low-risk i31-SLNB results who did not undergo the SLNB procedure, five-year RFS was 99.6%.
Together, these findings support using the test's i31-SLNB result to identify low-risk patients who may safely forgo SLNB and patients whose higher-risk result supports consideration of the procedure.
DecisionDx-Melanoma's 31-GEP Class result also significantly stratified five-year recurrence risk and provided prognostic information beyond traditional staging. Patients with early-stage disease (stage I–IIA) and high-risk Class 2B results had RFS similar to patients with stage IIB disease, supporting consideration of closer surveillance and additional treatment for patients whose higher risk may not be fully captured by staging alone.
A second abstract on DecisionDx-Melanoma will also be shared at EADV via an ePoster.